Onconetix Inc
NASDAQ:ONCO
Onconetix Inc
NASDAQ:ONCO
Price:
1.52
USD
-18.94%
Market Cap:
$1.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Onconetix Inc
NASDAQ:ONCO
|
US |
|
Wisdom Education International Holdings Company Ltd
HKEX:6068
|
CN |
|
N
|
Navan Inc
NASDAQ:NAVN
|
US |
|
International Endeavors Corp
OTC:IDVV
|
US |
|
S
|
Sable Exploration and Mining Ltd
JSE:SXM
|
ZA |
|
AllDigital Holdings Inc
OTC:ADGL
|
US |
|
Freewon China Co Ltd
SSE:688678
|
CN |
|
G
|
Guangzhou Rural Commercial Bank Co Ltd
HKEX:1551
|
CN |
|
C
|
Chu Kong Petroleum and Natural Gas Steel Pipe Holdings Ltd
HKEX:1938
|
CN |
|
M
|
Medcamp SA
WSE:MDP
|
PL |
|
G
|
Goto Ltd
TASE:GOTO
|
IL |
|
I
|
Infant Bacterial Therapeutics AB
STO:IBT B
|
SE |
|
Mizrahi Tefahot Bank Ltd
OTC:MZTFF
|
IL |
|
P
|
Profound Medical Corp
NASDAQ:PROF
|
CA |
|
P
|
Paliburg Holdings Ltd
HKEX:617
|
HK |
|
iEntertainment Network Inc
OTC:IENT
|
US |
Multiples-Based Value
The Multiples-Based Value of one
ONCO
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 1.52 USD,
Onconetix Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ONCO Multiples-Based Value
LOCKED
Multiples Across Competitors
ONCO Competitors Multiples
Onconetix Inc Competitors
Onconetix Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Onconetix Inc
NASDAQ:ONCO
|
1.1m USD | 1.3 | -0.1 | 0.7 | 0.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD | 6 | 88.2 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.2 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.4B USD | 5.9 | 20.4 | 12.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.4B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD | 5.6 | 17.9 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3.1 | 34 | 11.3 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
